StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.85+0.02 (+1.98%)

Close on Nov 18, 2026Market cap $14.23MP/E –Yield –

Marker Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Marker Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$10.71M. For fiscal 2025 it was -$12.89M. The highest annual figure on record is -$2.66M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.89M–
FY2024Dec 31, 2024-$11.12M–
FY2023Dec 31, 2023-$14.58M–
FY2022Dec 31, 2022-$19.79M–
FY2021Dec 31, 2021-$39.48M–
FY2020Dec 31, 2020-$28.89M–
FY2019Dec 31, 2019-$22.53M–
FY2018Dec 31, 2018-$148.17M–
FY2017Dec 31, 2017-$11.48M–
FY2016Dec 31, 2016-$8.49M–
FY2015Dec 31, 2015-$6.16M–
FY2014Dec 31, 2014-$3.37M–
FY2013Dec 31, 2013-$2.66M–
FY2011Dec 31, 2011-$3.32M–
FY2010Dec 31, 2010-$5.47M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.62M–
Q1 FY2026Mar 31, 2026-$4.07M–
Q4 FY2025Dec 31, 2025-$1.88M–
Q3 FY2025Sep 30, 2025-$2.14M–
Q2 FY2025Jun 30, 2025-$5.12M–
Q1 FY2025Mar 31, 2025-$4.96M–
Q4 FY2024Dec 31, 2024-$3.86M–
Q3 FY2024Sep 30, 2024-$2.40M–
Q2 FY2024Jun 30, 2024-$2.31M–
Q1 FY2024Mar 31, 2024-$2.55M–
Q4 FY2023Dec 31, 2023-$2.94M–
Q3 FY2023Sep 30, 2023-$3.20M–
Q2 FY2023Jun 30, 2023-$4.13M–
Q1 FY2023Mar 31, 2023-$4.31M–
Q4 FY2022Dec 31, 2022-$3.04M–
Q3 FY2022Sep 30, 2022-$5.83M–
Q2 FY2022Jun 30, 2022-$5.27M–
Q1 FY2022Mar 31, 2022-$9.79M–
Q4 FY2021Dec 31, 2021-$9.76M–
Q3 FY2021Sep 30, 2021-$10.02M–
Q2 FY2021Jun 30, 2021-$10.91M–
Q1 FY2021Mar 31, 2021-$8.78M–
Q4 FY2020Dec 31, 2020-$8.51M–
Q3 FY2020Sep 30, 2020-$7.38M–
Q2 FY2020Jun 30, 2020-$6.36M–
Q1 FY2020Mar 31, 2020-$6.64M–
Q4 FY2019Dec 31, 2019-$5.36M–
Q3 FY2019Sep 30, 2019-$5.65M–
Q2 FY2019Jun 30, 2019-$5.87M–
Q1 FY2019Mar 31, 2019-$5.64M–
Q2 FY2018Jun 30, 2018-$4.67M–
Q1 FY2018Mar 31, 2018-$3.20M–
Q4 FY2017Dec 31, 2017-$2.68M–
Q3 FY2017Sep 30, 2017-$3.99M–
Q2 FY2017Jun 30, 2017-$2.39M–
Q1 FY2017Mar 31, 2017-$2.42M–
Q4 FY2016Dec 31, 2016-$1.59M–
Q3 FY2016Sep 30, 2016-$2.72M–
Q2 FY2016Jun 30, 2016-$2.43M–

More Marker Therapeutics figures

See a number that looks wrong?